Phenylephrine gel - SLA Pharma

Drug Profile

Phenylephrine gel - SLA Pharma

Alternative Names: Incostop; SLV-325; VEN 308

Latest Information Update: 29 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SLA Pharma
  • Developer Assembly Biosciences; SLA Pharma
  • Class Antihypotensives; Decongestants; Ethanolamines; Mydriatics; Small molecules; Urologics
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Faecal incontinence

Most Recent Events

  • 29 Jul 2016 Discontinued - Phase-I for Faecal Incontinence in Europe (Rectal)
  • 27 Jul 2016 No recent reports on development identified - Phase-II for Faecal Incontinence in North America (Rectal)
  • 11 Jul 2014 Ventrus Biosciences has merged with Assembly Pharmaceuticals to form Assembly Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top